Intra-Cellular Therapies (ITCI) Reports Positive Phase 3 Topline Results from Study 501

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/29/2026

1. NOW
2. MSFT
3. GOOGL
4. FTNT
5. EBAY
6. BIIB
7. CMG
8. TENB
9. KLAC
10. ETSY

Go back to Intra-Cellular Therapies (ITCI) Reports Positive Phase 3 Topline Results from Study 501

Intra-Cellular Therapies Announces Positive Phase 3 Topline Results from Study 501 Evaluating Lumateperone as Adjunctive Therapy in Patients with Major Depressive Disorder

April 16, 2024 7:00 AM EDT

Lumateperone 42 mg achieved statistically significant and clinically meaningful results in both the primary and the key secondary endpoints

Lumateperone 42 mg met the primary endpoint of change from baseline at Week 6 on the Montgomery-Ã…sberg Depression Rating Scale (MADRS) total score versus placebo (4.9 point reduction v. placebo; p... More